Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1000+ biotech and pharma professionals? Let’s chat. 👍

Novartis, Daiichi Sankyo lands another Enhertu approval in China, this time in lung cancer
Antibody-drug conjugate, lung cancer - Read more

Novartis uses PRV for Kisqali supplement NDA
Small molecule, breast cancer, priority review voucher - Read more

Junshi Biosciences lands Chinese approval for ongericimab
Monoclonal antibody, hypercholesterolemia, mixed dyslipidemia - Read more

CMR Surgical scores FDA de novo clearance for laparoscopy robot
Surgical robot, laparoscopy - Read more

Soon to be Novo Holdings-owned Catalent sells New Jersey site to Ardena
CDMO, contract manufacturing, oral solids manufacturing - Read more

Nicox signs over Vyzulta royalties to Soleus Capital
Small molecule, glaucoma, ocular hypertension - Read more

GSK notches wins in two Ph3 trials for chronic nasal condition med depemokimab
Monoclonal antibody, chronic rhinosinusitis with nasal polyps - Read more

Eli Lilly showcases more Ph3 data for mirikizumab in Crohn's disease, potentially beating out incumbent Stelara (Johnson & Johnson)
Monoclonal antibody, Crohn's disease - Read more

Jasper Therapeutics’ positive positive preliminary Ph1b/2a data for briquilimab in chronic inducible urticaria
Monoclonal antibody, chronic inducible urticaria - Read more

Benitec Biopharma posts positive Ph1b/2a data for BB-301 in rare genetic disorder
Gene therapy, oculopharyngeal muscular dystrophy (OPMD), DNA-directed RNA interference - Read more

Looking to promote your biotech/pharma/life science-focused product or service to a captivated audience of industry professionals?

Consider sponsoring TLDR Biotech - your sponsored feature would go right here!

Want to take the next step (or just learn more)? Just reply to this email or message me on LinkedIn.

Shift Bioscience $16M raise
Gene-based interventions, aging, longevity - Read more [Paywall]

Inventiva secures €94.1 ($103M) equity financing
Small molecule, metabolic dysfunction-associated steatohepatitis (MASH), liver disease - Read more

Akeso Biopharma $250M share placement
Bispecific antibody, hypercholesterolemia, cancer - Read more

Eli Lilly ready to invest in new UK life sciences with £279M ($369M) towards new “Lilly Gateway Labs“ acclerator
Biotech accelerator, public-private partnership - Read more

Lundbeck buys Longboard Pharmaceuticals for $2.6B, rare brain disorder clinical assets
Small molecule, Dravet syndrome, Lennox-Gastaut syndrome - Read more

Blackstone and TPG consider buying Bausch + Lomb
Consumer health, ophthalmology, eye health - Read more

Merck & Co., Exelixis clinical development collab for zanzalintinib combined with Keytruda (in head & neck cancer) or Welireg (in renal cell carcinoma)
Small molecule, head & neck cancer, renal cell carcinoma, monoclonal antibody - Read more

Take it to the bank? BMO Capital Markets expects little difference between US election outcomes on the pharma industry
US election, pharmaceutical reform, inflation reduction act - Read more

Earlier use of Roche’s SMA med Evrysdi tied to better outcomes; study
Small molecule, spinal muscular atrophy - Read more

Bruker makes moves in spatial biology, combining tech acquired from NanoString and Canopy Biosciences under one roof
Spatial biology, instrumentation, cell-based discovery - Read more

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉

Pfizer unveils more detailed Ph3 results from failed DMD effort
Gene therapy, Duchenne muscular dystrophy - Read more [Paywall]

Novartis ends LTP001 Ph2 study in idiopathic pulmonary fibrosis after disappointing results, though has hopes for same med in pulmonary arterial hypertension
Small molecule, idiopathic pulmonary fibrosis, pulmonary arterial hypertension - Read more

Transgene’s cancer vaccine TG4001 fails Ph2, though holding out hope for a “positive efficacy trend”
Cancer vaccine, cervical cancer, canogenital cancer, oncolytic virus - Read more

Novo Nordisk’s counsels have no worries about job security as they go after GLP-1 compounders; 18 lawsuits in 44 days
GLP-1, obesity, compounding pharmacy - Read more [Paywall]

Evonik continues scale-down trend, up to 260 jobs cut in Germany
Small molecule, contract manufacturing - Read more

SalioGen Therapeutics looks to be laying off a lot of people; insider info + employee social media posts
Gene-editing, Stargardt, Usher syndrome - Read more [Paywall]

Vanda Pharmaceuticals playing hard-to-get, turns down another buyout offer from Cycle Pharmaceuticals
Small molecule, gastroparesis - Read more

For now, AI chatbots aren’t great with conveying drug safety information, sometimes incorrect and written at too-high a grade level; study
AI, drug safety - Read more

COVID-19 infection correlates with increased type 2 diabetes risk in pediatric patients; observational study
COVID-19, type 2 diabetes - Read more

Molecular Templates’ board approves liquidation plans
Engineered toxin bodies, cancer, solid tumor, myeloma - Read more

Vial design for Biogen, Eisai’s Leqembi could result in Medicare wasting $133M+ annually, as approximately 5.8% of the drug per vial remains unused, discarded due to dosing by patient weight
Monoclonal antibody, Alzheimer’s disease - Read more

Up to an estimated 130k cancer diagnoses that weren’t caught in 2020 (routine screens/check-ups paused during COVID) still remain unaccounted for
Diagnostic, cancer screening - Read more [Paywall]

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here